These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 19280324)
1. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Trevaskis NL; Shackleford DM; Charman WN; Edwards GA; Gardin A; Appel-Dingemanse S; Kretz O; Galli B; Porter CJ Pharm Res; 2009 Jun; 26(6):1486-95. PubMed ID: 19280324 [TBL] [Abstract][Full Text] [Related]
2. Lymphatic transport of Methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU. White KL; Nguyen G; Charman WN; Edwards GA; Faassen WA; Porter CJ J Pharmacol Exp Ther; 2009 Nov; 331(2):700-9. PubMed ID: 19696095 [TBL] [Abstract][Full Text] [Related]
3. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs. Lespine A; Chanoit G; Bousquet-Melou A; Lallemand E; Bassissi FM; Alvinerie M; Toutain PL Eur J Pharm Sci; 2006 Jan; 27(1):37-43. PubMed ID: 16198549 [TBL] [Abstract][Full Text] [Related]
4. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). Trevaskis NL; McEvoy CL; McIntosh MP; Edwards GA; Shanker RM; Charman WN; Porter CJ Pharm Res; 2010 May; 27(5):878-93. PubMed ID: 20221896 [TBL] [Abstract][Full Text] [Related]
5. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. Khoo SM; Edwards GA; Porter CJ; Charman WN J Pharm Sci; 2001 Oct; 90(10):1599-607. PubMed ID: 11745718 [TBL] [Abstract][Full Text] [Related]
6. Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Khoo SM; Shackleford DM; Porter CJ; Edwards GA; Charman WN Pharm Res; 2003 Sep; 20(9):1460-5. PubMed ID: 14567642 [TBL] [Abstract][Full Text] [Related]
7. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol. Caliph SM; Faassen FW; Porter CJ J Pharm Pharmacol; 2014 Oct; 66(10):1377-87. PubMed ID: 24821499 [TBL] [Abstract][Full Text] [Related]
8. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Holm R; Porter CJ; Edwards GA; Müllertz A; Kristensen HG; Charman WN Eur J Pharm Sci; 2003 Sep; 20(1):91-7. PubMed ID: 13678797 [TBL] [Abstract][Full Text] [Related]
9. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. Shackleford DM; Faassen WA; Houwing N; Lass H; Edwards GA; Porter CJ; Charman WN J Pharmacol Exp Ther; 2003 Sep; 306(3):925-33. PubMed ID: 12807999 [TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety. Gardin A; Kucher K; Kiese B; Appel-Dingemanse S Drug Metab Dispos; 2009 Apr; 37(4):827-33. PubMed ID: 19144772 [TBL] [Abstract][Full Text] [Related]
11. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. Caliph SM; Charman WN; Porter CJ J Pharm Sci; 2000 Aug; 89(8):1073-84. PubMed ID: 10906731 [TBL] [Abstract][Full Text] [Related]
12. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Holm R; Porter CJ; Müllertz A; Kristensen HG; Charman WN Pharm Res; 2002 Sep; 19(9):1354-61. PubMed ID: 12403073 [TBL] [Abstract][Full Text] [Related]
13. 2-Monoacylglycerol Mimetic Liposomes to Promote Intestinal Lymphatic Transport for Improving Oral Bioavailability of Dihydroartemisinin. Zheng B; Pan F; Shi M; He C; He B; Wang R; Ren G; Yang S; Zhang S Int J Nanomedicine; 2024; 19():5273-5295. PubMed ID: 38859952 [TBL] [Abstract][Full Text] [Related]
14. Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues. Caliph SM; Faassen WA; Vogel GM; Porter CJ Curr Drug Deliv; 2009 Aug; 6(4):359-66. PubMed ID: 19534711 [TBL] [Abstract][Full Text] [Related]
15. Examination of lymphatic transport of puerarin in unconscious lymph duct-cannulated rats after administration in microemulsion drug delivery systems. Wu H; Zhou A; Lu C; Wang L Eur J Pharm Sci; 2011 Mar; 42(4):348-53. PubMed ID: 21216284 [TBL] [Abstract][Full Text] [Related]
16. Intestinal lymphatic drug transport: an update. Porter CJ; Charman WN Adv Drug Deliv Rev; 2001 Aug; 50(1-2):61-80. PubMed ID: 11489334 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic Oral Absorption Modeling of Halofantrine: Exploring the Role of Intestinal Lymphatic Transport. Dolton MJ; Chiang PC; Chen Y J Pharm Sci; 2021 Mar; 110(3):1427-1430. PubMed ID: 33359312 [TBL] [Abstract][Full Text] [Related]
18. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Franco V; Gershkovich P; Perucca E; Bialer M Clin Pharmacokinet; 2020 Dec; 59(12):1493-1500. PubMed ID: 32785853 [TBL] [Abstract][Full Text] [Related]
19. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Holm R; Müllertz A; Christensen E; Høy CE; Kristensen HG Eur J Pharm Sci; 2001 Dec; 14(4):331-7. PubMed ID: 11684408 [TBL] [Abstract][Full Text] [Related]
20. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Managuli RS; Raut SY; Reddy MS; Mutalik S Expert Opin Drug Deliv; 2018 Aug; 15(8):787-804. PubMed ID: 30025212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]